Exponent (EXPO) PT Raised to $75 at Cantor Fitzgerald Following 2Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pre-Open Stock Movers 07/19: (AEZS) (VRTX) (SNI) Higher; (DRYS) (NTRS) (HDP) Lower (more...)
July 19, 2017 9:26 AM EDTToday's Pre-Open Stock Movers
Aeterna Zentaris Inc. (NASDAQ: AEZS) 48% HIGHER; announced that it has been notified by the U.S. Food and Drug Administration (FDA), that the Companys New Drug Application (NDA) seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults (AGHD) has been accepted as a complete response to the FDAs November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017.
DryShips Inc. (NASDAQ: DRYS) 30.8% LOWER; announced today... More
After-Hours Stock Movers 07/18: (AEZS) (VRTX) (EXPO) Higher; (DRYS) (HDP) (IBM) (CSX) (UAL) Lower (more...)
July 18, 2017 6:06 PM EDTToday's After-Hours Movers
Aeterna Zentaris Inc. (NASDAQ: AEZS) 31.4% HIGHER; announced that it has been notified by the U.S. Food and Drug Administration (FDA), that the Companys New Drug Application (NDA) seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults (AGHD) has been accepted as a complete response to the FDAs November 5, 2014 Complete Response Letter and granted a PDUFA date of December 30, 2017.
DryShips Inc. (NASDAQ: DRYS) 26.9% LOWER; announced today that its Board... More
UPDATE: Exponent, Inc. (EXPO) Tops Q2 EPS by 10c
July 18, 2017 4:06 PM EDT(Updated - July 18, 2017 4:09 PM EDT)
(updated to add guidance outlook)
Exponent, Inc. (NASDAQ: EXPO) reported Q2 EPS of $0.51, $0.10 better than the analyst estimate of $0.41. Revenue for the quarter came in at $87.84 million versus the consensus estimate of $81.21... More
Exponent, Inc. (EXPO) Declares $0.21 Quarterly Dividend; 1.4% Yield
July 18, 2017 4:05 PM EDTExponent, Inc. (NASDAQ: EXPO) declared a quarterly dividend of $0.21 per share, or $0.84 annualized.
The dividend will be payable on September 22, 2017, to stockholders of record on September 1, 2017, with an ex-dividend date of August 30, 2017.
The annual yield on the dividend is 1.4 percent.
For a... More
